Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic ...

@article{1621276,
   author = {Gojo, Johannes and Pavelka, Zdeněk and Zapletalová, Danica and Schmook, Maria T. and Mayr, Lisa and Madlener, Sibylle and Kýr, Michal and Vejmělková, Klára and Smrčka, Martin and Czech, Thomas and Dorfer, Christian and Skotáková, Jarmila and Azizi, Amedeo A. and Chocholous, Monika and Reisinger, Dominik and Laštovička, David and Valík, Dalibor and Haberler, Christine and Peyrl, Andreas and Nosková, Hana and Pál, Karol and Ježová, Marta and Veselská, Renata and Kozáková, Šárka and Slabý, Ondřej and Slavc, Irene and Štěrba, Jaroslav},
   article_location = {Lausanne},
   article_number = {JAN 10 2020},
   doi = {http://dx.doi.org/10.3389/fonc.2019.01436},
   keywords = {diffuse midline glioma; pediatric oncology; precision medicine; comprehensive molecular profiling},
   language = {eng},
   issn = {2234-943X},
   journal = {Frontiers in Oncology},
   title = {Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic Opportunities},
   url = {https://www.frontiersin.org/articles/10.3389/fonc.2019.01436/full},
   volume = {9},
   year = {2020}
}

TY  - JOUR
ID  - 1621276
AU  - Gojo, Johannes - Pavelka, Zdeněk - Zapletalová, Danica - Schmook, Maria T. - Mayr, Lisa - Madlener, Sibylle - Kýr, Michal - Vejmělková, Klára - Smrčka, Martin - Czech, Thomas - Dorfer, Christian - Skotáková, Jarmila - Azizi, Amedeo A. - Chocholous, Monika - Reisinger, Dominik - Laštovička, David - Valík, Dalibor - Haberler, Christine - Peyrl, Andreas - Nosková, Hana - Pál, Karol - Ježová, Marta - Veselská, Renata - Kozáková, Šárka - Slabý, Ondřej - Slavc, Irene - Štěrba, Jaroslav
PY  - 2020
TI  - Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic Opportunities
JF  - Frontiers in Oncology
VL  - 9
IS  - JAN 10 2020
SP  - 1-14
EP  - 1-14
PB  - Frontiers Media S.A.
SN  - 2234943X
KW  - diffuse midline glioma
KW  - pediatric oncology
KW  - precision medicine
KW  - comprehensive molecular profiling
UR  - https://www.frontiersin.org/articles/10.3389/fonc.2019.01436/full
N2  - Diffuse gliomas with K27M histone mutations (H3K27M glioma) are generally characterized by a fatal prognosis, particularly affecting the pediatric population. Based on the molecular heterogeneity observed in this tumor type, personalized treatment is considered to substantially improve therapeutic options. Therefore, clinical evidence for therapy, guided by comprehensive molecular profiling, is urgently required. In this study, we analyzed feasibility and clinical outcomes in a cohort of 12 H3K27M glioma cases treated at two centers. Patients were subjected to personalized treatment either at primary diagnosis or disease progression and received backbone therapy including focal irradiation. Molecular analyses included whole-exome sequencing of tumor and germline DNA, RNA-sequencing, and transcriptomic profiling. Patients were monitored with regular clinical as well as radiological follow-up. In one case, liquid biopsy of cerebrospinal fluid (CSF) was used. Analyses could be completed in 83% (10/12) and subsequent personalized treatment for one or more additional pharmacological therapies could be recommended in 90% (9/10). Personalized treatment included inhibition of the PI3K/AKT/mTOR pathway (3/9), MAPK signaling (2/9), immunotherapy (2/9), receptor tyrosine kinase inhibition (2/9), and retinoic receptor agonist (1/9). The overall response rate within the cohort was 78% (7/9) including one complete remission, three partial responses, and three stable diseases. Sustained responses lasting for 28 to 150 weeks were observed for cases with PIK3CA mutations treated with either miltefosine or everolimus and additional treatment with trametinib/dabrafenib in a case with BRAFV600E mutation. Immune checkpoint inhibitor treatment of a case with increased tumor mutational burden (TMB) resulted in complete remission lasting 40 weeks. Median time to progression was 29 weeks. Median overall survival (OS) in the personalized treatment cohort was 16.5 months. Last, we compared OS to a control cohort (n = 9) showing a median OS of 17.5 months. No significant difference between the cohorts could be detected, but long-term survivors (>2 years) were only present in the personalized treatment cohort. Taken together, we present the first evidence of clinical efficacy and an improved patient outcome through a personalized approach at least in selected cases of H3K27M glioma.
ER  - 

GOJO, Johannes, Zdeněk PAVELKA, Danica ZAPLETALOVÁ, Maria T. SCHMOOK, Lisa MAYR, Sibylle MADLENER, Michal KÝR, Klára VEJMĚLKOVÁ, Martin SMRČKA, Thomas CZECH, Christian DORFER, Jarmila SKOTÁKOVÁ, Amedeo A. AZIZI, Monika CHOCHOLOUS, Dominik REISINGER, David LAŠTOVIČKA, Dalibor VALÍK, Christine HABERLER, Andreas PEYRL, Hana NOSKOVÁ, Karol PÁL, Marta JEŽOVÁ, Renata VESELSKÁ, Šárka KOZÁKOVÁ, Ondřej SLABÝ, Irene SLAVC a Jaroslav ŠTĚRBA. Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic Opportunities. Online. \textit{Frontiers in Oncology}. Lausanne: Frontiers Media S.A., 2020, roč.~9, JAN 10 2020, s.~1-14. ISSN~2234-943X. Dostupné z: https://dx.doi.org/10.3389/fonc.2019.01436. [citováno 2024-04-24]